Loading company…
Tvaster Genkalp develops blood-based tests for detecting and monitoring liver cancer.
Tvaster Genkalp develops an epigenetic liquid biopsy for early detection and monitoring of Hepatocellular Carcinoma (HCC). Its Episcreen Liver test is designed for people with chronic liver disease who are at elevated risk of liver cancer. Founded in 2021, the company is based in Chennai, India. In April 2025, it raised USD 1.25 mn in pre-Series A funding led by Ideaspring Capital, with Invigo Software participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in